Cantor Fitzgerald Maintains Overweight on Ascendis Pharma, Lowers Price Target to $170
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Li Watsek maintains an Overweight rating on Ascendis Pharma (NASDAQ:ASND) but lowers the price target from $173 to $170.
September 04, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cantor Fitzgerald's analyst Li Watsek continues to rate Ascendis Pharma as Overweight, indicating a positive outlook, but slightly reduces the price target from $173 to $170.
The Overweight rating suggests a positive outlook, but the slight reduction in the price target may indicate some caution. The impact on the stock price is likely neutral as the overall sentiment remains positive.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100